How are SYK strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SYK strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 26.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$900.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a SYK strangle?

The breakeven for the SYK strangle priced on this page is roughly $281.00 and $329.00 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SYK market-implied 1-standard-deviation expected move is approximately 7.71%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current SYK implied volatility affect this strangle?

SYK ATM IV is at 26.90% with IV rank near 41.40%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

SYK Strangle Strategy

SYK (Stryker Corporation), in the Healthcare sector, (Medical - Devices industry), listed on NYSE.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants.

SYK (Stryker Corporation) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $115.70B, a trailing P/E of 34.66, a beta of 0.81 versus the broader market, a 52-week range of 281-404.87, average daily share volume of 2.1M, a public-listing history dating back to 1980, approximately 53K full-time employees. These structural characteristics shape how SYK stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.81 places SYK roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. SYK pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.

What is a strangle on SYK?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current SYK snapshot

As of May 15, 2026, spot at $307.71, ATM IV 26.90%, IV rank 41.40%, expected move 7.71%. The strangle on SYK below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on SYK specifically: SYK IV at 26.90% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 7.71% (roughly $23.73 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SYK expiries trade a higher absolute premium for lower per-day decay. Position sizing on SYK should anchor to the underlying notional of $307.71 per share and to the trader's directional view on SYK stock.

SYK strangle setup

The SYK strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SYK near $307.71, the first option leg uses a $320.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SYK chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SYK shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$320.00	$5.45
Buy 1	Put	$290.00	$3.55

SYK strangle risk and reward

Net Premium / Debit: -$900.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$900.00
Breakeven(s): $281.00, $329.00
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

SYK strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on SYK. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$28,099.00
$68.05	-77.9%	+$21,295.47
$136.08	-55.8%	+$14,491.94
$204.12	-33.7%	+$7,688.42
$272.15	-11.6%	+$884.89
$340.19	+10.6%	+$1,118.64
$408.22	+32.7%	+$7,922.17
$476.26	+54.8%	+$14,725.69
$544.29	+76.9%	+$21,529.22
$612.33	+99.0%	+$28,332.75

When traders use strangle on SYK

Strangles on SYK are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SYK chain.

SYK thesis for this strangle

The market-implied 1-standard-deviation range for SYK extends from approximately $283.98 on the downside to $331.44 on the upside. A SYK long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current SYK IV rank near 41.40% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on SYK should anchor more to the directional view and the expected-move geometry. As a Healthcare name, SYK options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SYK-specific events.

SYK strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SYK positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SYK alongside the broader basket even when SYK-specific fundamentals are unchanged. Always rebuild the position from current SYK chain quotes before placing a trade.

Frequently asked questions

What is a strangle on SYK?: A strangle on SYK is the strangle strategy applied to SYK (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With SYK stock trading near $307.71, the strikes shown on this page are snapped to the nearest listed SYK chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are SYK strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SYK strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 26.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$900.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a SYK strangle?: The breakeven for the SYK strangle priced on this page is roughly $281.00 and $329.00 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SYK market-implied 1-standard-deviation expected move is approximately 7.71%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on SYK?: Strangles on SYK are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SYK chain.
How does current SYK implied volatility affect this strangle?: SYK ATM IV is at 26.90% with IV rank near 41.40%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.